The dose-response of the anal sphincter region--an analysis of data from the MRC RT01 trial.
about
Technical aspects of radiation therapy for anal cancer.Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysisRelationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancerDose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions.Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy.An image-based method to quantify biomechanical properties of the rectum in radiotherapy of prostate cancer.Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapySpatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy.Radiotherapy dose-distribution to the perirectal fat space (PRS) is related to gastrointestinal control-related complications.Investigating rectal toxicity associated dosimetric features with deformable accumulated rectal surface dose maps for cervical cancer radiotherapy.Association between EBRT dose volume histograms and quality of life in prostate cancer patientsAno-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy
P2860
Q33820797-845E1A54-AE56-455A-B663-80194325FF2AQ34500966-00040C6F-B684-413B-AD76-347A576BB94DQ36672732-19BAA259-1CAB-43A1-ADAD-3D126A8302EFQ38612461-D4906037-98E3-4997-A8BB-1A080D555DD8Q38977242-34E5BF2A-4FA4-4660-8404-DA1E83B762AFQ38982334-2D2BF331-6E9D-4CEC-9776-87CB532F59FAQ39725461-AA5F624C-F11C-454A-926F-963B9AA8F7C8Q43365011-45A4C743-2894-4EA7-BBC3-5C8389247224Q44243863-ABDC387F-4A5B-4D37-AADB-BDB67D94FFC1Q52385231-C70CA3EA-DE07-4C25-A223-30F95A6A4416Q55279439-87FC0FA1-84A9-431F-9E5B-55CB84CF3923Q55502427-78A1F17B-2BA1-401D-9A0F-35A9F3A1CA53Q57166124-B4387FA7-07BA-4156-8108-746ACCDAF388Q59136739-BC1B6454-EF49-4CA8-9BCE-BAE9B8724C67
P2860
The dose-response of the anal sphincter region--an analysis of data from the MRC RT01 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The dose-response of the anal ...... data from the MRC RT01 trial.
@ast
The dose-response of the anal ...... data from the MRC RT01 trial.
@en
The dose-response of the anal ...... data from the MRC RT01 trial.
@nl
type
label
The dose-response of the anal ...... data from the MRC RT01 trial.
@ast
The dose-response of the anal ...... data from the MRC RT01 trial.
@en
The dose-response of the anal ...... data from the MRC RT01 trial.
@nl
prefLabel
The dose-response of the anal ...... data from the MRC RT01 trial.
@ast
The dose-response of the anal ...... data from the MRC RT01 trial.
@en
The dose-response of the anal ...... data from the MRC RT01 trial.
@nl
P2093
P50
P1476
The dose-response of the anal ...... data from the MRC RT01 trial.
@en
P2093
David P Dearnaley
Sarah L Gulliford
Steve Webb
P304
P356
10.1016/J.RADONC.2012.03.002
P577
2012-04-18T00:00:00Z